癌治療薬の世界市場

世界の癌治療薬の市場規模は、2023年の1,964億米ドルから、予測期間中は12.7%のCAGRで推移し、2029年には4,014億米ドルに達すると予測されています。

標的療法の部門は、2023年の804億米ドルから、14.1%のCAGRで推移し、2029年には1,766億米ドルに達すると予測されています。免疫療法の部門は、2023年の754億米ドルから、12.6%のCAGRで推移し、2029年には1,525億米ドルに達すると予測されています。

当レポートでは、世界の癌治療薬の市場を調査し、市場概要、市場影響因子および市場機会の分析、法規制環境、新興技術および技術開発の動向、市場規模の推移・予測、各種区分・地域別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 エグゼクティブサマリー

• 市場見通し
• 調査範囲
• 市場概要

第2章 市場概要

• 概要
• サプライチェーン分析
• 研究開発
• 製造
• 包装
• 卸売・再包装
• 薬局
• 消費者への分配
• 医薬品サプライチェーンの課題への取り組み
• コスト
• 規則
• 安全・セキュリティ
• ポーターのファイブフォース分析

第3章 市場力学

• 市場力学
• 市場促進要因
• 癌の発症率の増加
• 抗癌剤の順調な承認
• 癌治療における技術の進歩
• 市場の課題
• 独占性の喪失と一般化
• 腫瘍学専門家の不足

第4章 新たな動向とパイプライン分析

• 新興技術
• パーソナライズドワクチン
• CAR T細胞療法
• 乳癌リスクを軽減するタブレット
• ナノ粒子
• 加圧腹腔内エアロゾル化学療法 (PIPAC)
• 新たな展開
• バイオシミラーの承認
• パイプライン分析
• 臨床試験分析
• 特許分析

第5章 市場セグメンテーション分析

• セグメンテーションの内訳
• 世界の癌治療薬市場：薬剤タイプ別
• 免疫療法
• 標的療法
• 化学療法
• ホルモン療法
• 世界の癌治療薬市場：癌タイプ別
• 肺癌
• 乳癌
• 白血病
• 悪性黒色腫
• 多発性骨髄腫
• 前立腺癌
• 非ホジキンリンパ腫
• 大腸癌
• その他の癌
• 地理的内訳
• 世界の癌治療薬市場：地域別
• 北米
• 欧州
• アジア太平洋
• その他

第6章 競合情報

• 概要
• 腫瘍のブロックバスター医薬品ブランド
• 主要企業の市場シェア

第7章 癌治療薬市場における持続可能性：ESGの観点

• 製薬業におけるESGの役割
• 環境
• 社交
• ガバナンス
• ESGリスク評価
• 総論

第8章 付録

• 調査手法
• 出典
• 頭字語
• 企業プロファイル
• ABBVIE INC.
• AMGEN INC.
• ASTRAZENECA
• BRISTOL-MYERS SQUIBB CO.
• F. HOFFMANN-LA ROCHE LTD.
• JOHNSON & JOHNSON SERVICES INC.
• LILLY
• MERCK & CO. INC.
• NOVARTIS AG
• PFIZER INC.
• SANOFI
• TAKEDA PHARMACEUTICAL CO. LTD.

List of Tables

• Summary Table : Global Oncology Pharmaceuticals Market, by Drug Type, Through 2029
• Table 1 : Number of Oncology Drug Approvals, 2020-2024*
• Table 2 : Novel Oncology Drug Approvals, 2021-2024*
• Table 3 : FDA Approved Biosimilar for Oncology Indications, 2015-2024
• Table 4 : Overview of Biosimilars and Interchangeable Biosimilars Approved, by FDA
• Table 5 : EMA Approved Biosimilar for Oncology Indications, 2007-2024
• Table 6 : List of Selected Clinical Trials Studies on Oncology Drugs Started in 2021
• Table 7 : List of Selected Clinical Trials Studies on Oncology Drugs Started in 2022
• Table 8 : List of Selected Clinical Trials Studies on Oncology Drugs Started in 2023
• Table 9 : List of Selected Clinical Trials Studies on Oncology Drugs Started in 2024
• Table 10 : Top IPCR Classification Codes and Their Descriptions
• Table 11 : Global Oncology Pharmaceuticals Market, by Drug Type, Through 2029
• Table 12 : Global Oncology Pharmaceuticals Market for Immunotherapy Drugs, by Region, Through 2029
• Table 13 : Global Oncology Pharmaceuticals Market for Immunotherapy Drugs, by Type, Through 2029
• Table 14 : FDA-Approved Immune Checkpoint Inhibitor Drugs and Their Disease Indications
• Table 15 : Global Oncology Pharmaceuticals Market for Targeted Therapy Drugs, by Type, Through 2029
• Table 16 : Global Oncology Pharmaceuticals Market for Targeted Therapy Drugs, by Region, Through 2029
• Table 17 : Global Oncology Pharmaceuticals Market for Chemotherapy Drugs, by Region, Through 2029
• Table 18 : Global Oncology Pharmaceuticals Market for Hormone Therapy Drugs, by Region, Through 2029
• Table 19 : Global Oncology Pharmaceuticals Market, by Cancer Type, Through 2029
• Table 20 : Global Oncology Pharmaceuticals Market for Lung Cancer, by Region, Through 2029
• Table 21 : Global Oncology Pharmaceuticals Market for Breast Cancer, by Region, Through 2029
• Table 22 : Global Oncology Pharmaceuticals Market for Leukemia, by Region, Through 2029
• Table 23 : Global Oncology Pharmaceuticals Market for Melanoma, by Region, Through 2029
• Table 24 : Global Oncology Pharmaceuticals Market for Multiple Myeloma, by Region, Through 2029
• Table 25 : Global Oncology Pharmaceuticals Market for Prostate Cancer, by Region, Through 2029
• Table 26 : Global Oncology Pharmaceuticals Market for Non-Hodgkin's Lymphoma, by Region, Through 2029
• Table 27 : Global Oncology Pharmaceuticals Market for Colorectal Cancer, by Region, Through 2029
• Table 28 : Global Oncology Pharmaceuticals Market for Other Type of Cancers, by Region, Through 2029
• Table 29 : Global Oncology Pharmaceuticals Market, by Region, Through 2029
• Table 30 : North American Oncology Pharmaceuticals Market, by Drug Type, Through 2029
• Table 31 : North American Oncology Pharmaceuticals Market, by Cancer Type, Through 2029
• Table 32 : North American Market for Oncology Pharmaceuticals, by Country, Through 2029
• Table 33 : U.S. Oncology Pharmaceuticals Market, by Drug Type, Through 2029
• Table 34 : U.S. Oncology Pharmaceuticals Market, by Cancer Type, Through 2029
• Table 35 : Canadian Oncology Pharmaceuticals Market, by Drug Type, Through 2029
• Table 36 : Canadian Oncology Pharmaceuticals Market, by Cancer Type, Through 2029
• Table 37 : Mexican Oncology Pharmaceuticals Market, by Drug Type, Through 2029
• Table 38 : Mexican Oncology Pharmaceuticals Market, by Cancer Type, Through 2029
• Table 39 : European Oncology Pharmaceuticals Market, by Drug Type, Through 2029
• Table 40 : European Oncology Pharmaceuticals Market, by Cancer Type, Through 2029
• Table 41 : European Market for Oncology Pharmaceuticals Market, by Country, Through 2029
• Table 42 : German Oncology Pharmaceuticals Market, by Drug Type, Through 2029
• Table 43 : German Oncology Pharmaceuticals Market, by Cancer Type, Through 2029
• Table 44 : U.K. Oncology Pharmaceuticals Market, by Drug Type, Through 2029
• Table 45 : U.K. Oncology Pharmaceuticals Market, by Cancer Type, Through 2029
• Table 46 : French Oncology Pharmaceuticals Market, by Drug Type, Through 2029
• Table 47 : French Oncology Pharmaceuticals Market, by Cancer Type, Through 2029
• Table 48 : Spanish Oncology Pharmaceuticals Market, by Drug Type, Through 2029
• Table 49 : Spanish Oncology Pharmaceuticals Market, by Cancer Type, Through 2029
• Table 50 : Italian Oncology Pharmaceuticals Market, by Drug Type, Through 2029
• Table 51 : Italian Oncology Pharmaceuticals Market, by Cancer Type, Through 2029
• Table 52 : Rest of the European Oncology Pharmaceuticals Market, by Drug Type, Through 2029
• Table 53 : Rest of the European Oncology Pharmaceuticals Market, by Cancer Type, Through 2029
• Table 54 : Asia-Pacific Oncology Pharmaceuticals Market, by Drug Type, Through 2029
• Table 55 : Asia-Pacific Oncology Pharmaceuticals Market, by Cancer Type, Through 2029
• Table 56 : Asia-Pacific Market for Oncology Pharmaceuticals, by Country, Through 2029
• Table 57 : Chinese Oncology Pharmaceuticals Market, by Drug Type, Through 2029
• Table 58 : Chinese Oncology Pharmaceuticals Market by Cancer Type, Through 2029
• Table 59 : Japanese Oncology Pharmaceuticals Market, by Drug Type, Through 2029
• Table 60 : Japanese Oncology Pharmaceuticals Market, by Cancer Type, Through 2029
• Table 61 : Indian Oncology Pharmaceuticals Market, by Drug Type, Through 2029
• Table 62 : Indian Oncology Pharmaceuticals Market, by Cancer Type, Through 2029
• Table 63 : South Korean Oncology Pharmaceuticals Market, by Drug Type, Through 2029
• Table 64 : South Korean Oncology Pharmaceuticals Market by Cancer Type, Through 2029
• Table 65 : Rest of Asia-Pacific Oncology Pharmaceuticals Market, by Drug Type, Through 2029
• Table 66 : Rest of Asia-Pacific Oncology Pharmaceuticals Market, by Cancer Type, Through 2029
• Table 67 : Rest of World Oncology Pharmaceuticals Market, by Drug Type, Through 2029
• Table 68 : Rest of World Oncology Pharmaceuticals Market, by Cancer Type, Through 2029
• Table 69 : ESG Risk Rankings for Oncology Pharmaceuticals Companies, 2023*
• Table 70 : Report Information Sources
• Table 71 : Glossary of Terms Used in the Global Oncology Pharmaceuticals Market
• Table 72 : AbbVie Inc.: Company Snapshot
• Table 73 : AbbVie Inc.: Financial Performance, FY 2022 and 2023
• Table 74 : AbbVie Inc.: Product Portfolio
• Table 75 : AbbVie Inc.: News/Key Developments, 2023 and 2024
• Table 76 : Amgen Inc.: Company Snapshot
• Table 77 : Amgen Inc.: Financial Performance, FY 2022 and 2023
• Table 78 : Amgen Inc.: Product Portfolio
• Table 79 : Amgen Inc.: News/Key Developments, 2022-2024
• Table 80 : AstraZeneca: Company Snapshot
• Table 81 : AstraZeneca: Financial Performance, FY 2022 and 2023
• Table 82 : AstraZeneca: Product Portfolio
• Table 83 : AstraZeneca: News/Recent Developments, 2022-2024
• Table 84 : Bristol-Myers Squibb Co.: Company Snapshot
• Table 85 : Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023
• Table 86 : Bristol-Myers Squibb Co.: Product Portfolio
• Table 87 : Bristol-Myers Squibb Co.: News/Key Developments, 2023 and 2024
• Table 88 : F. Hoffmann-La Roche Ltd.: Company Snapshot
• Table 89 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
• Table 90 : F. Hoffmann-La Roche Ltd.: Product Portfolio
• Table 91 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022-2024
• Table 92 : Johnson & Johnson Services Inc.: Company Snapshot
• Table 93 : Johnson & Johnson Services Inc.: Financial Performance, FY 2022 and 2023
• Table 94 : Johnson & Johnson Services Inc.: Product Portfolio
• Table 95 : Johnson & Johnson Services Inc.: News/Key Developments, 2022-2024
• Table 96 : Lilly: Company Snapshot
• Table 97 : Lilly: Financial Performance, FY 2022 and 2023
• Table 98 : Lilly: Product Portfolio
• Table 99 : Lilly: News/Key Developments, 2023 and 2024
• Table 100 : Merck & Co. Inc.: Company Snapshot
• Table 101 : Merck & Co. Inc.: Financial Performance, FY 2022 and 2023
• Table 102 : Merck & Co. Inc.: Product Portfolio
• Table 103 : Merck & Co. Inc.: News/Key Developments, 2021-2024
• Table 104 : Novartis AG: Company Snapshot
• Table 105 : Novartis AG: Financial Performance, FY 2022 and 2023
• Table 106 : Novartis AG: Product Portfolio
• Table 107 : Novartis AG: News/Key Developments, 2022-2024
• Table 108 : Pfizer Inc.: Company Snapshot
• Table 109 : Pfizer Inc.: Financial Performance, FY 2022 and 2023
• Table 110 : Pfizer Inc.: Product Portfolio
• Table 111 : Pfizer Inc.: News/Key Developments, 2021-2024
• Table 112 : Sanofi: Company Snapshot
• Table 113 : Sanofi: Financial Performance, FY 2022 and 2023
• Table 114 : Sanofi: Product Portfolio
• Table 115 : Sanofi: News/Key Developments, 2022-2024
• Table 116 : Takeda Pharmaceutical Co. Ltd.: Company Snapshot
• Table 117 : Takeda Pharmaceutical Co. Ltd.: Financial Performance, FY 2022 and 2023
• Table 118 : Takeda Pharmaceutical Co. Ltd.: Product Portfolio
• Table 119 : Takeda Pharmaceutical Co. Ltd.: News/Key Developments, 2021-2024

List of Figures

• Summary Figure : Global Oncology Pharmaceuticals Market, by Drug Type, 2021-2029
• Figure 1 : Supply Chain Process of Pharmaceutical Drugs
• Figure 2 : Market Dynamics of Global Oncology Pharmaceuticals Market
• Figure 3 : Cancer Incidence in the U.S., 2000-2021
• Figure 4 : Share of Incidence Cases of All Cancer Types, Both Sexes, by WHO Region, 2022
• Figure 5 : Novel Oncology Drugs with FDA Approvals, 2016-2024
• Figure 6 : Clinical Trial Studies of Oncology Drugs, by Trial Phase, 2021-2024*
• Figure 7 : Clinical Trial Studies of Oncology Drugs, by Company, 2021-2024
• Figure 8 : Top IPCR Classification Codes, 2020-2024
• Figure 9 : Global Oncology Pharmaceuticals Market Share, by Drug Type, 2023
• Figure 10 : Global Oncology Pharmaceuticals Market Share for Immunotherapy Drugs, by Region, 2023
• Figure 11 : Global Oncology Pharmaceuticals Market Share for Targeted Therapy, by Region, 2023
• Figure 12 : Timeline for U.S. FDA-Approved Small Molecule Inhibitors Targeting Cancers
• Figure 13 : Global Oncology Pharmaceuticals Market Share for Chemotherapy Drugs, by Region, 2023
• Figure 14 : Global Oncology Pharmaceuticals Market Share for Hormone Therapy Drugs, by Region, 2023
• Figure 15 : Global Oncology Pharmaceuticals Market Share, by Cancer Type, 2023
• Figure 16 : Share of Global Cancer Incidence Cases in Both Sexes, by Cancer Type, 2022
• Figure 17 : Share of Global Cancer Mortality Cases in Both Sexes, by Cancer Type, 2022
• Figure 18 : Global Lung Cancer Incidence and Mortality Numbers in Both Sexes, by WHO Region, 2022
• Figure 19 : Global Oncology Pharmaceuticals Market Share for Lung Cancer, by Region, 2023
• Figure 20 : Global Breast Cancer Incidence and Mortality Numbers in Both Sexes, by WHO Region, 2022
• Figure 21 : Global Oncology Pharmaceuticals Market Share for Breast Cancer, by Region, 2023
• Figure 22 : Global Leukemia Incidence and Mortality Numbers in Both Sexes, by WHO Region, 2022
• Figure 23 : Global Oncology Pharmaceuticals Market Share for Leukemia, by Region, 2023
• Figure 24 : Global Melanoma Incidence and Mortality Numbers in Both Sexes, by WHO Region, 2022
• Figure 25 : Global Oncology Pharmaceuticals Market Share for Melanoma, by Region, 2023
• Figure 26 : Global Multiple Myeloma Cancer Incidence and Mortality Numbers in Both Sexes, by WHO Region, 2022
• Figure 27 : Global Oncology Pharmaceuticals Market Share for Multiple Myeloma, by Region, 2023
• Figure 28 : Global Prostate Cancer Incidence and Mortality Numbers in Both Sexes, by WHO Region, 2022
• Figure 29 : Global Oncology Pharmaceuticals Market Share for Prostate Cancer, by Region, 2023
• Figure 30 : Global Non-Hodgkin's Lymphoma Cancer Incidence and Mortality Numbers in Both Sexes, by WHO Region, 2022
• Figure 31 : Global Oncology Pharmaceuticals Market Share for Non-Hodgkin's Lymphoma, by Region, 2023
• Figure 32 : Global Colon Cancer Incidence and Mortality Numbers in Both Sexes, by WHO Region, 2022
• Figure 33 : Global Oncology Pharmaceuticals Market Share for Colorectal Cancer, by Region, 2023
• Figure 34 : Global Oncology Pharmaceuticals Market Share for Other Type of Cancers, by Region, 2023
• Figure 35 : Global Oncology Pharmaceuticals Market Share, by Region, 2023
• Figure 36 : North American Market Share of Oncology Pharmaceuticals, by Country, 2023
• Figure 37 : European Market Share of Oncology Pharmaceuticals, by Country, 2023
• Figure 38 : Asia-Pacific Market Share of Oncology Pharmaceuticals, by Country, 2023
• Figure 39 : Top 10 Blockbuster Oncology Pharmaceutical Drugs, by Sales Revenue, 2023
• Figure 40 : Company Share Analysis of Oncology Pharmaceutical Manufacturers, 2023
• Figure 41 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 42 : AbbVie Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 43 : Amgen Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 44 : Amgen Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 45 : AstraZeneca: Revenue Share, by Business Unit, FY 2023
• Figure 46 : AstraZeneca: Revenue Share, by Region/Country, FY 2023
• Figure 47 : Bristol-Myers Squibb Co.: Revenue Share, by Business Unit, FY 2023
• Figure 48 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2023
• Figure 49 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2023
• Figure 50 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2023
• Figure 51 : Johnson & Johnson Services Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 52 : Johnson & Johnson Services Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 53 : Lilly: Revenue Share, by Business Unit, FY 2023
• Figure 54 : Lilly: Revenue Share, by Country/Region, FY 2023
• Figure 55 : Merck & Co. Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 56 : Merck & Co. Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 57 : Novartis AG: Revenue Share, by Business Unit, FY 2023
• Figure 58 : Novartis AG: Revenue Share, by Country/Region, FY 2023
• Figure 59 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 60 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 61 : Sanofi: Revenue Share, by Business Unit, FY 2023
• Figure 62 : Sanofi: Revenue Share, by Country/Region, FY 2023
• Figure 63 : Takeda Pharmaceutical Co. Ltd.: Revenue Share, by Business Unit, FY 2023
• Figure 64 : Takeda Pharmaceutical Co. Ltd.: Revenue Share, by Region, FY 2023

The global market for oncology pharmaceuticals is estimated to increase from $196.4 billion in 2023 to reach $401.4 billion by 2029, at a compound annual growth rate (CAGR) of 12.7% from 2024 through 2029.

The targeted therapy market for oncology pharmaceuticals is estimated to increase from $80.4 billion in 2023 to reach $176.6 billion by 2029, at a CAGR of 14.1% from 2024 through 2029.

The immunotherapy market for oncology pharmaceuticals is estimated to increase from $75.4 billion in 2023 to reach $152.5 billion by 2029, at a CAGR of 12.6% from 2024 through 2029.

Report Scope

This report seeks to deliver an in-depth analysis of the worldwide oncology pharmaceuticals (cancer medications) market. It includes a thorough overview of various types of oncology drugs, such as targeted therapy, immunotherapy, chemotherapy, and hormone therapy, and an examination of current and historical market revenues. The oncology pharmaceuticals market is further categorized by indication, including lung cancer, multiple myeloma, breast cancer, non-Hodgkin's lymphoma, prostate cancer, colorectal cancer, and other types of cancer. Additionally, the report presents the market revenue for each geographic region, including North America, Europe, Asia-Pacific, and the Rest of the World (RoW).

In order to provide an in-depth understanding of the market, this report also includes profiles of market participants, the competitive landscape, key competitors, and respective market share/ranking. This report includes an oncology pharmaceuticals pipeline analysis, patent analysis, and a detailed discussion of key marketed products. This report outlines the driving and restraining factors of the oncology pharmaceuticals market.

By geography, the market in this report is segmented into four regions: North America, Europe, Asia-Pacific, and Rest of the World (RoW). For market estimates, data has been provided for 2023 as the base year, with forecasts for 2024 through 2029.

Report Includes

• 70 data tables and 50 additional tables
• Analysis of the global market for oncology pharmaceuticals (cancer drugs)
• Analyses of global market trends, with market revenue data from 2022 to 2023, estimates for 2024, forecast for 2025, and projected CAGRs through 2029
• An assessment of the different oncology pharmaceutical types (targeted therapy, immunotherapy, chemotherapy and hormone therapy) and their current and historical market revenues
• Estimate of the current market size and revenue prospects, along with a market share analysis by drug type, disease indication (application type), and region
• Facts and figures pertaining to the market dynamics, technological advances, regulations, and the macroeconomic factors that influence the industry
• A Porter's Five Forces model, and global supply chain and PESTLE analyses
• An analysis of the key products on the market and promising new pipeline molecules or drugs under development
• A look at the recent patent grants
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, ESG score analysis, and the ESG practices of leading companies
• Analysis of the industry structure, including companies' market shares, strategic alliances, M&A activity and a venture funding outlook
• Company profiles of major players within the industry, including Bristol-Myers Squibb Co., Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., and AstraZeneca.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary

Chapter 2 Market Overview

• Overview
• Supply Chain Analysis
• Research and Development
• Manufacturing
• Packaging
• Wholesale Distributors and Repackagers
• Pharmacies
• Dispensed to Consumers
• Addressing Challenges in the Pharmaceutical Supply Chain
• Costs
• Regulations
• Safety and Security
• Porter's Five Forces Analysis in the Oncology Market
• Threat of New Entrants
• Bargaining Power of Suppliers
• Bargaining Power of Buyers
• Threat of Substitute Products or Services
• Industry Rivalry

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Increasing Incidence of Cancer Disease
• Robust Approval of Oncology Drugs
• Technological Advances in Cancer Treatments
• Market Challenges
• Loss of Exclusivity and Genericization
• Lack of Oncology Professionals

Chapter 4 Emerging Trends and Pipeline Analysis

• Emerging Technologies
• Personalized Cancer Vaccines
• CAR T-Cell Therapy
• Tablet to Cut Breast Cancer Risk
• Nanoparticles
• Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)
• New Developments
• Biosimilar Approvals
• Pipeline Analysis
• Clinical Trial Analysis
• Patent Analysis

Chapter 5 Market Segmentation Analysis

• Segmentation Breakdown
• Global Oncology Pharmaceuticals Market by Drug Type
• Immunotherapy
• Targeted Therapy
• Chemotherapy
• Hormone Therapy
• Global Oncology Pharmaceuticals Market by Cancer Type
• Lung Cancer
• Breast Cancer
• Leukemia
• Melanoma
• Multiple Myeloma
• Prostate Cancer
• Non-Hodgkin's Lymphoma
• Colorectal Cancer
• Other Cancers
• Geographic Breakdown
• Global Oncology Pharmaceuticals Market by Region
• North America
• Europe
• Asia-Pacific
• Rest of World

Chapter 6 Competitive Intelligence

• Overview
• Blockbuster Oncology Pharmaceutical Brands
• Global Market Shares of Leading Companies

Chapter 7 Sustainability in the Oncology Pharmaceuticals Market: ESG Perspective

• Role of ESG in the Pharma Industry
• Environmental
• Social
• Governance
• ESG Risk Ratings
• Conclusion

Chapter 8 Appendix

• Methodology
• Sources
• Acronyms
• Company Profiles
• ABBVIE INC.
• AMGEN INC.
• ASTRAZENECA
• BRISTOL-MYERS SQUIBB CO.
• F. HOFFMANN-LA ROCHE LTD.
• JOHNSON & JOHNSON SERVICES INC.
• LILLY
• MERCK & CO. INC.
• NOVARTIS AG
• PFIZER INC.
• SANOFI
• TAKEDA PHARMACEUTICAL CO. LTD.